The use of low dose oral cyclophosphamide-methotrexate maintenance following adjuvant chemotherapy may benefit patients with hormone receptor-negative early breast cancer
.jpg)
During the American Society of Clinical Oncology (ASCO) metting held on June 1 2015, Marco A. Colleoni, Director of the IEO Division of Medical Senology and Scientific Committee Chair ot the IBCSG (International Breast Cancer Study Group) presented the results of Trial 22-00: Cyclophosphamide-Methotrexate Maintenance (CMM).
“Women with hormone receptor-negative breast cancer face a higher risk of early disease recurrence, and there is currently no targeted treatment available for patients with triple negative breast cancer,” comments Dr. Marco A. Colleoni. “This is the first trial to test the efficacy of adding a low dose oral cyclophosphamide-methotrexate maintenance component to adjuvant chemotherapy treatment for hormone receptor-negative breast cancer. While the disease-free survival benefits are not statistically significant, they are promising – especially for triple-negative patients.”
"Adding low dose oral cyclophosphamide-methotrexate maintenance to adjuvant chemotherapy reduced the relative risk of developing breast cancer recurrence by 16% in women with hormone receptor-negative early breast cancer, when compared to treatment with adjuvant chemotherapy alone. This observed benefit was greater in women with triple-negative disease".